We carried out maintenance treatments for patients with tyrosine kinase inhibitors such as sorafenib for FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutated AML and dasatinib for Philadelphia chromosome-positive ALL (Ph+ ALL). Here, FLT3 is linked to acute lymphoblastic leukemia.